CN104857534A - 叶酸盐靶向的诊断和治疗 - Google Patents

叶酸盐靶向的诊断和治疗 Download PDF

Info

Publication number
CN104857534A
CN104857534A CN201510160314.2A CN201510160314A CN104857534A CN 104857534 A CN104857534 A CN 104857534A CN 201510160314 A CN201510160314 A CN 201510160314A CN 104857534 A CN104857534 A CN 104857534A
Authority
CN
China
Prior art keywords
patient
tumor
folate
purposes
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510160314.2A
Other languages
English (en)
Chinese (zh)
Inventor
C.P.利蒙
R.梅斯曼
D.摩尔金斯特恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CN104857534A publication Critical patent/CN104857534A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201510160314.2A 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗 Pending CN104857534A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US61/230595 2009-07-31
US34644410P 2010-05-19 2010-05-19
US61/346444 2010-05-19
US35102210P 2010-06-03 2010-06-03
US61/351022 2010-06-03
CN2010800434602A CN102549434A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800434602A Division CN102549434A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Publications (1)

Publication Number Publication Date
CN104857534A true CN104857534A (zh) 2015-08-26

Family

ID=43529728

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510160314.2A Pending CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗
CN2010800434602A Pending CN102549434A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800434602A Pending CN102549434A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Country Status (13)

Country Link
US (2) US20120128587A1 (cg-RX-API-DMAC7.html)
EP (1) EP2460013A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013501224A (cg-RX-API-DMAC7.html)
KR (1) KR20120050462A (cg-RX-API-DMAC7.html)
CN (2) CN104857534A (cg-RX-API-DMAC7.html)
AU (1) AU2010278734A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012002064A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769754A1 (cg-RX-API-DMAC7.html)
IL (1) IL217744A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01708A (cg-RX-API-DMAC7.html)
NZ (1) NZ598145A (cg-RX-API-DMAC7.html)
RU (1) RU2012105641A (cg-RX-API-DMAC7.html)
WO (1) WO2011014821A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110678204A (zh) * 2016-03-29 2020-01-10 恩多塞特公司 用于靶向肿瘤相关巨噬细胞的叶酸缀合物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US8987281B2 (en) 2010-11-12 2015-03-24 Endocyte, Inc. Methods of treating cancer
CN103607891A (zh) * 2011-04-12 2014-02-26 恩多塞特公司 固体药用组合物
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
WO2015055796A1 (en) 2013-10-16 2015-04-23 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
EP3574924B1 (en) 2013-11-19 2021-01-06 Purdue Research Foundation Patient selection method for inflammation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20170368208A1 (en) * 2015-01-11 2017-12-28 Endocyte, Inc. Cancer imaging agent
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN121337736A (zh) * 2025-12-16 2026-01-16 临沂市人民医院 多柔比星与免疫调节剂共载脂质体的制备及其协同抗肿瘤用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601332B2 (en) * 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
JP5243041B2 (ja) * 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
DE602006012816D1 (de) * 2005-03-30 2010-04-22 Endocyte Inc Tifizierung von zellulären folat vitamin rezeptoren
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
MX2009004555A (es) * 2006-10-25 2009-05-11 Schering Corp Metodos de tratamiento de cancer de ovario.
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER P. LEAMON ET AL: ""Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145"", 《INT. J. CANCER》 *
ENDOCYTE ET AL: "Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate", 《CANCER RES》 *
LEVI S. DOWNS JR ET AL: "A Prospective Randomized Trial of Thalidomide With Topotecan Compared With Topotecan Alone in Women With Recurrent Epithelial Ovarian Carcinoma", 《CANCER》 *
RONALD E. FISHER ET AL: "Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor–Positive Solid Tumors", 《J NUCL MED》 *
TIMOTHY A. YAP ET AL: "Beyond chemotherapy: targeted therapies in ovarian cancer", 《CANCER》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110678204A (zh) * 2016-03-29 2020-01-10 恩多塞特公司 用于靶向肿瘤相关巨噬细胞的叶酸缀合物

Also Published As

Publication number Publication date
KR20120050462A (ko) 2012-05-18
US20140140925A1 (en) 2014-05-22
RU2012105641A (ru) 2013-09-10
IN2012DN01708A (cg-RX-API-DMAC7.html) 2015-06-05
BR112012002064A2 (pt) 2017-05-09
IL217744A0 (en) 2012-03-29
EP2460013A1 (en) 2012-06-06
CA2769754A1 (en) 2011-02-03
EP2460013A4 (en) 2013-04-03
US20120128587A1 (en) 2012-05-24
WO2011014821A1 (en) 2011-02-03
AU2010278734A1 (en) 2012-02-23
NZ598145A (en) 2014-10-31
JP2013501224A (ja) 2013-01-10
CN102549434A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
US20140140925A1 (en) Folate-targeted diagnostics and treatment
US8987281B2 (en) Methods of treating cancer
JP2019520328A (ja) Ｐｅｔイメージング用免疫修飾因子
EP2795317B1 (en) Composition for use in a method for cancer selection
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
WO2023202730A2 (zh) 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途
HK1172952A (en) Folate-targeted diagnostics and treatment
Xie et al. CuET Radiosensitizes FAP-Targeted Radioligand Therapy in Lung Cancer by inhibiting DNA Repair
KR20250109190A (ko) 암의 식별 및/또는 치료
AU2015203646A1 (en) Folate-targeted diagnostics and treatment
AU2013204342A1 (en) Methods of treating cancer
HK1189272B (en) Methods of treating cancer
HK1189057A (en) Methods of treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150826

WD01 Invention patent application deemed withdrawn after publication